Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
[Treatment of neuromyelitis optica].
Ultra-high field MRI: looking through the 'macroscope'
Relative changes in ankle and hip control during bilateral joint movements in persons with multiple sclerosis.
Premature immune senescence in children with MS: Too young to go steady.
Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of multiple sclerosis.
Neuroimaging assessment of spasticity developed after acquired brain injuries and multiple sclerosis.
A case of simultaneous neuromyelitis optica spectrum disorder and subacute combined degeneration.
Predictive value of health-related quality of life in progression of disability and depression in persons with multiple sclerosis: a 3-year study.
Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis.
Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
Bochum ultrasound score versus clinical and electrophysiological parameters in distinguishing acute-onset chronic from acute inflammatory demyelinating polyneuropathy.
Rotation-invariant multi-contrast non-local means for MS lesion segmentation.
Teriflunomide - a new oral agent for multiple sclerosis treatment.
Role of socioeconomic position in multiple sclerosis etiology.
Using conceptual work products of case management to design health IT.
Biochemical Pharmacology of the Sigma-1 Receptor.
Defining reliable disability outcomes in multiple sclerosis.
Erratum to: Advancing drug delivery systems for the treatment of multiple sclerosis.
In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology.
Is there a cognitive signature for MS-related fatigue?
Quantitative PCR Analysis of DNA Aptamer Pharmacokinetics in Mice.
In-silico prediction of drug targets, biological activities, signal pathways and regulating networks of dioscin based on bioinformatics.
Role of socio-economic and reproductive factors in the risk of multiple sclerosis.
Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: Results from a longitudinal study.
A 62-year-old man with fluctuating neurological deficits and skin lesions.
Pages
« first
‹ previous
…
543
544
545
546
547
548
549
550
551
…
next ›
last »